Taiwan’s TLC signs U.S./EU Sandoz deal for amphotericin B
By Dave Silver
Tuesday, December 24, 2013
TAIPEI, Taiwan – Taiwan Liposome Co. Ltd. (TLC), of Taipei, recently signed a distribution agreement giving Sandoz AG, the generics drug affiliate of Novartis AG, of Basel, Switzerland, distribution rights in the European Union (EU) and U.S. for TLC’s generic version of Gilead Sciences Inc.’s Ambisome, a liposomal rendering of antifungal drug amphotericin B.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.